US · BVS
Bioventus Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Durham, NC 27703
- Website
- bioventus.com
Price · as of 2024-12-31
$10.11
Market cap 588.05M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.17 | +178.64% |
| Intrinsic Value(DCF) | $3.68 | -63.6% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $0.00 | |||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $1.74 | |||
| 2020 | $14.35 | $25.58 | $2.44 | $0.00 | $1.21 |
| 2021 | $13.97 | $42.82 | $45.94 | $8.86 | $17.40 |
| 2022 | $1.62 | $58.29 | $1.62 | $0.00 | $0.00 |
| 2023 | $5.40 | $52.80 | $0.00 | $0.00 | $0.00 |
| 2024 | $9.20 | $28.17 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Bioventus Inc.'s (BVS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.17
- Current price
- $10.11
- AI upside
- +178.64%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.68
-63.6% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BVS | Bioventus Inc. | $10.11 | 588.05M | +179% | -64% | — | — | -1890.78 | 4.06 | 1.05 | 22.83 | — | -2.28 | 67.72% | -2.09% | -5.85% | -0.20% | -2.20% | -0.04% | 2.27 | -0.31 | 1.31 | 0.80 | 7.50 | -7912.00% | 1189.00% | 37343.00% | 6.28% | 0.18 | 7.76% | 0.00% | 0.00% | 10.62% | -74.74 | 23.69 | 1.56 | 0.82 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| CTKB | Cytek Biosciences, Inc. | $4.48 | 572.83M | +597% | -46% | — | — | -8.51 | 1.66 | 2.81 | -18.31 | -0.83 | 1.84 | 51.84% | -20.04% | -33.02% | -18.05% | -35.25% | -13.85% | 0.04 | -85.20 | 5.04 | 4.16 | 4.42 | 102798.00% | 52.00% | -14013.00% | -1.55% | -0.06 | -7.65% | 0.00% | 0.00% | 0.00% | -7.88 | -36.31 | 1.58 | 3.49 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Bioventus Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
- CEO
- Robert E. Claypoole
- Employees
- 930
- Beta
- 0.79
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.68 ÷ $10.11) − 1 = -63.6% (DCF, example).